- Home
- OABI vs IGMS Comparison
OABI vs IGMS Comparison
Compare OABI & IGMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OABI
- IGMS
- Stock Information
- Founded
- OABI 2012
- IGMS 1993
- Country
- OABI United States
- IGMS United States
- Employees
- OABI N/A
- IGMS N/A
- Industry
- OABI Biotechnology: Pharmaceutical Preparations
- IGMS Biotechnology: Pharmaceutical Preparations
- Sector
- OABI Health Care
- IGMS Health Care
- Exchange
- OABI Nasdaq
- IGMS Nasdaq
- Market Cap
- OABI 388.5M
- IGMS 348.5M
- IPO Year
- OABI N/A
- IGMS 2019
- Fundamental
- Price
- OABI $3.22
- IGMS $1.71
- Analyst Decision
- OABI Strong Buy
- IGMS Hold
- Analyst Count
- OABI 4
- IGMS 8
- Target Price
- OABI $9.00
- IGMS $6.14
- AVG Volume (30 Days)
- OABI 448.8K
- IGMS 783.1K
- Earning Date
- OABI 11-12-2024
- IGMS 03-06-2025
- Dividend Yield
- OABI N/A
- IGMS N/A
- EPS Growth
- OABI N/A
- IGMS N/A
- EPS
- OABI N/A
- IGMS N/A
- Revenue
- OABI $20,409,000.00
- IGMS $2,918,000.00
- Revenue This Year
- OABI N/A
- IGMS $23.57
- Revenue Next Year
- OABI $78.61
- IGMS $192.36
- P/E Ratio
- OABI N/A
- IGMS N/A
- Revenue Growth
- OABI N/A
- IGMS 57.64
- 52 Week Low
- OABI $3.16
- IGMS $1.59
- 52 Week High
- OABI $6.55
- IGMS $22.50
- Technical
- Relative Strength Index (RSI)
- OABI 32.70
- IGMS 19.36
- Support Level
- OABI $3.16
- IGMS $1.59
- Resistance Level
- OABI $3.29
- IGMS $2.06
- Average True Range (ATR)
- OABI 0.13
- IGMS 0.41
- MACD
- OABI -0.02
- IGMS -0.25
- Stochastic Oscillator
- OABI 9.09
- IGMS 2.18
About OABI OmniAb Inc.
OmniAb Inc offers therapeutic antibody discovery technologies. The company focuses on enabling the rapid development of therapeutics by pushing the frontiers of drug discovery technologies. Its technology platform is designed to enable the efficient discovery of high-quality, fully human antibodies for a wide range of diseases. The heart of the OmniAb technology platform is the Biological Intelligence of its proprietary transgenic animals, including OmniRat, OmniMouse, and OmniChicken, that have been genetically modified to generate antibodies with human sequences which are naturally optimized through in vivo affinity maturation.
About IGMS IGM Biosciences Inc.
IGM Biosciences Inc is a biotechnology company engaged in the development of IgM antibody therapeutics for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. Its IgM antibody technology platform is suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Its product candidate, Aplitabart: An IgM antibody targeting Death Receptor 5 (DR5) proteins, for the treatment of colorectal cancer; Imvotamab: A bispecific for severe systemic lupus erythematosus (SLE) and one for severe rheumatoid arthritis (RA); and IGM-2644: A bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins, currently planned for evaluation in autoimmune disease.